Biosimilars Market - Forecasts from 2025 to 2030

The Biosimilars Market will reach US$50.901 billion in 2030 from US$24.176 billion in 2025 at a CAGR of 16.06% during the forecast period.

Biosimilars are defined as licensed and highly similar versions of biological drugs that have already been approved for use by regulatory bodies. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics, coupled with the patent expiration of the many blockbuster biologic drugs. The estimated patent and exclusivity expiry of a few of the blockbuster biologics is given below. Due to the structural complexity of biosimilar drugs, multi-layered manufacturing, and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market.

Biosimilars Market Growth Drivers

The market is propelled by increasing corporate investments in biosimilar development.

Biosimilars Market Regional Insights

Europe dominates the global biosimilars market, driven by the presence of leading biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, and Merck. A well-established regulatory framework for biosimilar approvals, a growing number of product approvals, and advanced healthcare infrastructure further fuel market growth in Europe. North America is also expected to experience significant growth during the forecast period, supported by heightened focus on product development and manufacturers' efforts to capitalize on regional growth opportunities.

Market intelligence is delivered through detailed analysis, charts, and graphics, enabling clients to quickly and effectively understand the global biosimilars market.

The Biosimilars Market Report offers a comprehensive analysis of the industry, providing strategic and executive-level insights backed by data-driven forecasts. This regularly updated report empowers decision-makers with actionable intelligence on market trends, emerging opportunities, and competitive dynamics. Biosimilars are defined as biologic products highly similar to licensed biologic drugs, with minor differences in inactive components. The report also examines technological advancements, key government policies, regulatory frameworks, and macroeconomic factors, delivering a holistic market perspective.

Some of the major players covered in this report include Samsung Bioepis, Stada Arzneimittel AG, Sandoz International GmbH (Novartis), Amgen Inc., Apotex Inc., BioCad, Dr. Reddy's Laboratories Ltd., Biocon, Boehringer Ingelheim International GmbH, Pfizer, BioFactura, and AmerisourceBergen Corporation among others.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Biosimilars Market Segmentations:

Biosimilars Market Segmentation by Type

The market is analyzed by type into the following:

• Monoclonal antibodies
• Erythropoietins (EPO)
• Granulocyte-Colony Stimulating Factors (G-CSF)
• Interferons
• Hormone-based Biosimilars
• Others

Biosimilars Market Segmentation by Disease

The market is analyzed by disease into the following:

• Infectious Disease
• Oncology and Immunology
• Respiratory
• Genetic Disorders
• Others

Biosimilars Market Segmentation by Regions:

The study also analyzed the biosimilars in the following regions, with country-level forecasts and analysis as below:

• North America (US, Canada, and Mexico)
• South America (Brazil, Argentina, and Others)
• Europe (Germany, UK, France, Spain, and Others
• Middle East and Africa (Saudi Arabia, UAE, and Others)
• Asia Pacific (China, Japan, India, South Korea, Thailand, Indonesia, and Others)

Biosimilars Market Report Coverage:

This report provides extensive coverage as explained in the points below:

• Market size, forecasts, and trends by different types, with historical revenue data and analysis focusing on key factors driving adoption, current challenges faced by key players, and major growth areas.
• Market size, forecasts, and trends by technology, with historical revenue data and analysis.
• Market size, forecasts, and trends by application, with historical revenue data and analysis across various segments.
• The biosimilars market involves biologic drugs that are highly similar to reference products in terms of safety, purity, and potency. These drugs offer cost-effective alternatives to innovative biologics, making them attractive for treating chronic conditions like cancer and autoimmune diseases.
• Market dynamics: The section details the market growth factors, restraints, and opportunities in the market. The segment also presents a complete market scenario with the help of Porter's five forces model.
• Competitive Intelligence: A thorough investigation of the competitive structure of the market presented through a proprietary vendor matrix model, market share analysis of key players, insights on strategies of key players, and recent major developments undertaken by the companies to gain a competitive edge.
• Research methodology: The assumptions and sources that were considered to arrive at the final market estimates. Additionally, how our model is refined to ensure the most significant factors are taken into consideration with the proper hypothesis and bottom-up and top-down approaches enhance the reliability of forecasts further strengthening the trustworthiness of the numbers being presented.

How this report is helpful to you and reasons for the purchase?

• The report provides a strategic outlook of the surface computing market to the decision-makers, analysts, and other stakeholders in an easy-to-read format for making informed decisions.
• The charts, tables, and figures make it easy for the executives to gain valuable insights while skimming the report.
• Analyst support through calls and emails for timely clarification and incorporating additional requests.
• Option of presentation or doc format with the estimates file to take care of diverse requirements.
• 15% FREE customization with all our reports to help cater to additional requirements with significant cost savings.
• Option of purchasing specific segments of the study, including opting for summary reports or just the estimates file.